Litfulo (ritlecitinib)

Further studies are required for both molecules and to better understand responder and non-responder populations. Pfizer Inc.

P2, N=32, Recruiting, Pfizer | N=24 --> 32

P2, N=56, Not yet recruiting, Centre Hospitalier Universitaire de Nice | Trial primary completion date: Oct 2028 --> Jan 2029

P2, N=24, Recruiting, Pfizer | N=12 --> 24

P1/2, N=12, Not yet recruiting, Pfizer Inc.

The efficacy and safety of ritlecitinib, a dual inhibitor of Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases, have been demonstrated in the ALLEGRO phase 2b/3 trial that enrolled patients aged ≥ 12 years with alopecia areata (AA) and ≥ 50% scalp hair loss. A one-way sensitivity analysis showed that parameters with the most notable effect on the ICER were the utility for patients with SALT score ≥ 50, percentage of work time missed due to presenteeism for patients with SALT score ≥ 50, and the discontinuation rate of ritlecitinib 50 mg. These results indicate that ritlecitinib 50 mg is cost-effective compared with no treatment for patients with AA and hair loss on ≥ 50% of the scalp from a societal perspective in Japan.

P2, N=21, Recruiting, Pfizer

P=N/A, N=487, Active, not recruiting, Pfizer | N=191 --> 487

P3, N=607, Completed, Pfizer | Active, not recruiting --> Completed

P1/2, N=7, Not yet recruiting, Pfizer Inc.

P2/3, N=68, Recruiting, Pfizer Inc.

P2/3, N=78, Not yet recruiting, Pfizer Inc.